Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Follow-Up Questions
Qui est le CEO de WAVE Life Sciences Ltd ?
Dr. Paul Bolno est le President de WAVE Life Sciences Ltd, il a rejoint l'entreprise depuis 2013.
Quelle est la performance du prix de l'action WVE ?
Le prix actuel de WVE est de $7.89, il a increased de 1.08% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de WAVE Life Sciences Ltd ?
WAVE Life Sciences Ltd appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de WAVE Life Sciences Ltd ?
La capitalisation boursière actuelle de WAVE Life Sciences Ltd est de $1.2B
Est-ce que WAVE Life Sciences Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour WAVE Life Sciences Ltd, y compris 6 achat fort, 11 achat, 2 maintien, 0 vente et 6 vente forte
